Form 4: Abbott Laboratories Director Robert J. Alpern Reports Stock Equivalent Unit Acquisition

Director Robert J. Alpern reports acquisition of 69 stock equivalent units in Abbott Laboratories on September 30, 2024, through director fees credited to a grantor trust.

Summary

• Robert J. Alpern, a director of Abbott Laboratories, reported a transaction on September 30, 2024.
• Alpern acquired 69 stock equivalent units at a price of $114.01.
• These units were obtained through director fees credited to a stock equivalent unit account under a grantor trust.
• The stock equivalent units earn the same return as if the fees were invested in Abbott shares and are generally paid in cash at age 65 or upon retirement from the board.
• Following the transaction, Alpern directly owns 9,872 stock equivalent units, which includes units acquired through dividend reinvestments.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a routine transaction indicating continued investment by a director, which is generally viewed favorably.

Positives

• The director's acquisition of stock equivalent units demonstrates continued investment in the company's future.
• The dividend reinvestment feature allows for compounding returns on the stock equivalent units.

Future Outlook

The stock equivalent units are generally paid in cash at age 65 or upon retirement from the board, indicating a long-term investment strategy.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Related Party Transactions

• The crediting of director fees to a stock equivalent unit account under a grantor trust can be considered a related party transaction.

Stakeholder Impact

• The transaction signals confidence from a company director, which can positively influence shareholder sentiment.

Key Dates